Luca Issi
Stock Analyst at RBC Capital
(3.71)
# 740
Out of 5,149 analysts
220
Total ratings
49.64%
Success rate
7.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $13.99 | +7.22% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $240.55 | +14.32% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $750.32 | +18.62% | 4 | Feb 27, 2026 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $22 → $26 | $27.50 | -5.45% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $25 → $30 | $48.51 | -38.16% | 19 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $500 → $465 | $318.07 | +46.20% | 29 | Jan 20, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $79.10 | +20.10% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $65.14 | +22.81% | 11 | Dec 11, 2025 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $9 → $27 | $13.35 | +102.32% | 6 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $7 → $10 | $7.80 | +28.21% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $28.32 | -1.13% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $10.97 | -27.07% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $57.31 | -12.76% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $8.84 | +114.93% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $15.75 | +90.48% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $45 | $8.95 | +402.79% | 7 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.58 | +288.35% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $20.29 | -11.29% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $6.93 | +188.81% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.40 | +398.13% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $10.83 | +56.97% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $7.47 | +74.03% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $8.71 | +301.84% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $58.91 | +18.83% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $49.25 | +15.74% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.03 | +97.04% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $22.21 | +246.69% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.75 | +700.00% | 5 | Aug 7, 2024 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $13.99
Upside: +7.22%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $240.55
Upside: +14.32%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $750.32
Upside: +18.62%
Beam Therapeutics
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $27.50
Upside: -5.45%
Moderna
Feb 17, 2026
Maintains: Sector Perform
Price Target: $25 → $30
Current: $48.51
Upside: -38.16%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Outperform
Price Target: $500 → $465
Current: $318.07
Upside: +46.20%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $79.10
Upside: +20.10%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $65.14
Upside: +22.81%
Wave Life Sciences
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $13.35
Upside: +102.32%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $7.80
Upside: +28.21%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $28.32
Upside: -1.13%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $10.97
Upside: -27.07%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $57.31
Upside: -12.76%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $8.84
Upside: +114.93%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $15.75
Upside: +90.48%
Nov 4, 2025
Maintains: Outperform
Price Target: $65 → $45
Current: $8.95
Upside: +402.79%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.58
Upside: +288.35%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $20.29
Upside: -11.29%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $6.93
Upside: +188.81%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.40
Upside: +398.13%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $10.83
Upside: +56.97%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $7.47
Upside: +74.03%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $8.71
Upside: +301.84%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $58.91
Upside: +18.83%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $49.25
Upside: +15.74%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.03
Upside: +97.04%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $22.21
Upside: +246.69%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.75
Upside: +700.00%